STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMLX
  4. [Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity

Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Joshua B. Cohen received an equity award linked to company performance. On August 18, 2026, he acquired 60,039 shares of Common Stock represented by performance share units (PSUs) that vested on that date upon achievement of specified performance metrics. Following this vesting event, Cohen directly holds 3,643,587 shares of Amylyx Common Stock.

Positive

  • None.

Negative

  • None.
Insider Cohen Joshua B
Role Co-Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Stock F1 60,039 $0.00 $0.00
Holdings After Transaction: Common Stock — 3,643,587 shares (Direct)
Footnotes (1)
  1. F1. The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.
Shares acquired in award 60,039 shares of Common Stock Performance share units vesting on August 18, 2026
Price per share for award $0.00 per share Grant/award acquisition of Common Stock represented by PSUs
Total shares held after transaction 3,643,587 shares of Common Stock Direct ownership by Joshua B. Cohen following PSU vesting
Transaction date August 18, 2026 Vesting date for performance share units and share acquisition
Number of acquire-type transactions 1 transaction Form 4 transaction summary for this filing
performance share units financial
"The reported shares are represented by performance share units, or PSUs"
Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.
PSUs financial
"represented by performance share units, or PSUs, and were awarded"
PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.
vested financial
"Shares subject to the PSU vested on August 18, 2026"
grant/award acquisition financial
"transaction_action":"grant/award acquisition""

FAQ

What insider transaction did AMLX report for Joshua B. Cohen on this Form 4?
Joshua B. Cohen was reported to have acquired 60,039 shares of Amylyx Common Stock on August 18, 2026, through a grant classified as a performance-based equity award represented by performance share units (PSUs) that vested on that date.

How many AMLX shares does Joshua B. Cohen hold after this transaction?
After the August 18, 2026 PSU vesting, Joshua B. Cohen directly holds 3,643,587 shares of Amylyx Pharmaceuticals, Inc. Common Stock, as reported in the Form 4 filing.

What type of security was involved in Joshua B. Cohen’s AMLX Form 4 transaction?
The transaction involved Common Stock of Amylyx Pharmaceuticals, Inc., represented by performance share units (PSUs) that converted into shares upon satisfaction of certain performance metrics and vested on August 18, 2026.

Was the August 18, 2026 AMLX insider award a cash transaction?
No. The Form 4 reports a grant/award acquisition of 60,039 shares at a per-share transaction price of $0.00, reflecting a performance-based equity award rather than a market purchase for cash.

What triggered the vesting of Joshua B. Cohen’s performance share units at AMLX?
The filing states that the reported shares are represented by PSUs that were awarded upon achievement of certain performance metrics, and that the shares subject to the PSU vested on August 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cohen Joshua B
(Last)(First)(Middle)
C/O AMYLYX PHARMACEUTICALS, INC.
55 CAMBRIDGE PARKWAY, SUITE 6W
(Street)
CAMBRIDGE MASSACHUSETTS 02142
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Co-Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/18/2026A60,039(1)A$03,643,587D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.
/s/ Joshua B. Cohen08/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR